Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: NTTG who wrote (12131)	6/28/2013 3:10:38 PM
From: Mimbari	2 Recommendations Recommended By Howard Williams Jack Russell Read Replies (2) \| Respond to of 13111

Narrow Approval meant melanoma not stage III only. Once approved for melanoma it would be up to the doctor to use it on any cancer he wishes. NTTG your misinforming the public again. The FDA is not keen on AA or SPA or BTD for the most part. Yes NTTG, some drugs do get approved in each of those categories. They are underpaid and overworked and do not like having outside people telling them what they should do...i.e. congress making them do BTD. PVCT is working towards AA, SPA and BTD all at the same time I imagine. As far as time frames, most drugs take this amount of time or longer. There is no smoke screen other than NTTG's true motives for posting. Say, speaking of the faux doubter, where was NTTG at the share holders meeting, considering he works just a few miles away from where it was held? One would imagine the the great NTTG would have the perfect opportunity to hold managements feet to the fire or have answers to all his questions and doubts personally.